Possible effects of lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms on cardiovascular risk in patients with preeclampsia

References

• Craici I, Wagner S, Garovic VD. Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther Adv Cardiovasc Dis. 2008;2(4):249–259.
   PubMedGoogle Scholar
• Raymond D, Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv. 2011;66(8):497–506.
   PubMed Web of Science ®Google Scholar
• Smith GD, Harding S, Rosato M. Relation between infants’ birth weight and mothers’ mortality: prospective observational study. BMJ. 2000;320(7238):839–840.
   PubMedGoogle Scholar
• Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243–1262.
   PubMedGoogle Scholar
• Sibai BM, Gordon T, Thom E, et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. The National Institute of Child Health and Human Development Network of Maternal–Fetal Medicine Units. Am J Obstet Gynecol. 1995;172(2Pt1):642–648.
   Web of Science ®Google Scholar
• Sattar N, Bendomir A, Berry C, et al. Lipoprotein subfraction concentrations in preeclampsia: pathogenic parallels to atherosclerosis. Obstet Gynecol. 1997;89(3):403–408.
   PubMed Web of Science ®Google Scholar
• Hubel CA, Lyall F, Weissfeld L, et al. Small low-density lipoproteins and vascular cell adhesion molecule-1 are increased in association with hyperlipidemia in preeclampsia. Metabolism. 1998;47(10):1281–1288.
   PubMed Web of Science ®Google Scholar
• Anuurad E, Ozturk Z, Enkhmaa B, et al. Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians. J Clin Endocrinol Metab. 2010;95(5):2376–2383.
   PubMed Web of Science ®Google Scholar
• Burke JE, Dennis EA. Phospholipase A2 biochemistry. Cardiovasc Drugs Ther. 2009;23(1):49–59.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008;101(12A):51F–57F.
   PubMed Web of Science ®Google Scholar
• ACOG Committee on Practice Bulletins. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002;99(1):159–167.
   PubMed Web of Science ®Google Scholar
• Liu PY, Li YH, Wu HL, et al. Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction. J Thromb Haemost. 2006;4(5):1023–1028.
   PubMed Web of Science ®Google Scholar
• Lavi S, McConnell JP, Rihal CS, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 2007;115(21):2715–2721.
   PubMed Web of Science ®Google Scholar
• Yang EH, McConnell JP, Lennon RJ, et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol. 2006;26(1):106–111.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Alexander RW, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499–511.
   PubMed Web of Science ®Google Scholar
• Koenig W, Khuseyinova N, Löwel H, et al. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004;110(14):1903–1908.
   PubMed Web of Science ®Google Scholar
• Winkler K, Hoffmann MM, Winkelmann BR, et al. Predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Clin Chem. 2007;53(8):1440–1447, A2.
   PubMed Web of Science ®Google Scholar
• Cook NR, Paynter NP, Manson JE, et al. Clinical utility of lipoprotein-associated phospholipase A2 for cardiovascular disease prediction in a multiethnic cohort of women. Clin Chem. 2012;58(9):1352–1363.
   PubMed Web of Science ®Google Scholar
• Packard CJ, O’Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343(16):1148–1155.
   PubMed Web of Science ®Google Scholar
• Blake GJ, Dada N, Fox JC, et al. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001;38(5):1302–1306.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109(7):837–842.
   PubMed Web of Science ®Google Scholar
• Garlanda C, Bottazzi B, Bastone A, et al. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337–366.
   PubMed Web of Science ®Google Scholar
• Cozzi V, Garlanda C, Nebuloni M, et al. PTX3 as a potential endothelial dysfunction biomarker for severity of preeclampsia and IUGR. Placenta. 2012;33(12):1039–1044.
   PubMed Web of Science ®Google Scholar
• Latini R, Maggioni AP, Peri G, et al. . Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004;110(16):2349–2354.
   PubMed Web of Science ®Google Scholar
• Hamad RR, Eriksson MJ, Berg E, et al. Impaired endothelial function and elevated levels of PENTRAXIN 3 in early-onset preeclampsia. Acta Obstet Gynecol Scand. 2012;91(1):50–56.
   PubMed Web of Science ®Google Scholar
• Can M, Sancar E, Harma M, et al. Inflammatory markers in preeclamptic patients. Clin Chem Lab Med. 2011;49(9):1469–1472.
   PubMed Web of Science ®Google Scholar
• Belo L, Santos-Silva A, Rocha S, et al. Fluctuations in C-reactive protein concentration and neutrophil activation during normal human pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005;123(1):46–51.
   PubMed Web of Science ®Google Scholar
• Stríz I, Trebichavský I. Calprotectin – a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004;53(3):245–253.
   PubMed Web of Science ®Google Scholar
• Sutton BS, Crosslin DR, Shah SH, et al. Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets. Hum Mol Genet. 2008;17(9):1318–1328.
   PubMed Web of Science ®Google Scholar
• Ninio E, Tregouet D, Carrier JL, et al. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet. 2004;13(13):1341–1351.
   PubMed Web of Science ®Google Scholar